Term
|
Definition
| modifies gene expression; affects all immune cells; suppresses many proteins |
|
|
Term
|
Definition
| inhibits an enzyme required for the synetheisis of purines (adenine and guanine) |
|
|
Term
|
Definition
| inhibits purine and thymidine synthesis through inhibiting enzymes |
|
|
Term
|
Definition
| Inhibits DNA syntehsis by blocking de novo guanine synthesis |
|
|
Term
|
Definition
| alkylating agent- prevents DNA replication and protein production (more potent) |
|
|
Term
|
Definition
| alkylating agent- prevents DNA replication and protein production (less potent) |
|
|
Term
|
Definition
| works by inhibiting t cell activation by blocking IL-2 production |
|
|
Term
|
Definition
| inhibits calcineurin activation, blocking IL-2 production |
|
|
Term
|
Definition
| In T cells blocks signals from IL-2 receptor-- inhibits a protein called mTOR |
|
|
Term
|
Definition
| mouse mAb works to destroy t cells, Ab recognizes CD3 and causes t cells to be opsonized |
|
|
Term
|
Definition
| (horse);recognize many antigens; antibodies opsonize, fixing complement, ADCC |
|
|
Term
|
Definition
| (rabbit); recognize many antigens; antibodies opsonize, fixing complement, ADCC |
|
|
Term
|
Definition
| chimeric mAb; blocks IL2 binding to the IL2 receptor- more likely to affect t cells that are activated against graft antigens |
|
|
Term
|
Definition
| Form soluble receptors/fusion proteins; blocks normal function of TNF alpha |
|
|
Term
|
Definition
| Chimeric mAb; binding TNF alpha to block it from binding to its receptor |
|
|
Term
|
Definition
| Human mAb; binding TNF alpha to block it from binding to its receptor |
|
|
Term
| Certolizumab pegol (Cimzia) |
|
Definition
| pegylated humanized fab to TNF alpha; Fab fragment is able to block TNF alpha |
|
|
Term
|
Definition
| Recombinant form of a naturally occuring IL-1 receptor antagonist; binds to IL-1 receptor on target cells to keep IL-1 from binding |
|
|
Term
|
Definition
| Humanized mAb; binds IL-6 receptor to keep IL-6 from binding |
|
|
Term
|
Definition
| Soluble receptor/fusion protein; blocks B7---CD28 interaction by binding to B7 |
|
|
Term
|
Definition
| Soluble receptor/fusion molecule; blocks t cell activation by blocking adhesion between t cell and APC |
|
|
Term
|
Definition
| humanized mAb; block adhesion molecule on t cells that helps them move into brain and intestine |
|
|
Term
|
Definition
| Fungal metabolite; holding lymphocytes in the lymph nodes to keep them from entering blood and reaching the brain |
|
|
Term
|
Definition
| chimeric mAb; kill b cells that make antibodies that form complexes and cause type III hypersensitivity; binds CD20 |
|
|
Term
|
Definition
| humanized mAb; binds to IgE and blocks it from binding to the Fc receptor present on mast cells, eosinophils |
|
|
Term
|
Definition
| type 1 interferon; shuts off TH1 type immune responses and production of inflammatory cytokines; MOA not understood |
|
|
Term
| Homologous pooled human antibody |
|
Definition
| fix complement, activate ADCC, block, opsonize (remove IgE, not meant to activate allergies), all the normal functions of antibodies |
|
|
Term
| Homologous human hyper-immunoglobuline |
|
Definition
| Antibodies are collected from specific people with high levels of antibodies against the pathogen or antigen of interest |
|
|
Term
|
Definition
| Drug binds to D antigen on fetal RBCs to block mother from generating an immune response (prevent "hemolytic disease of the newborn") |
|
|
Term
| Heterologous hyper-immune serum |
|
Definition
| Collected from animals immunized with a specific antigen. Often its a toxin or a venom; blocks/neutralizes |
|
|
Term
|
Definition
| Humanized mAb; recognizes respiratory syncytial virus (RSV), no RSV vaccination- usually occurs in children (provides passive immunity) |
|
|
Term
|
Definition
| adjuvant used in human vaccines; aluminum salt suspended in gel |
|
|
